Literature DB >> 29262395

Salvianolic Acid A Protects Against Diabetic Nephropathy through Ameliorating Glomerular Endothelial Dysfunction via Inhibiting AGE-RAGE Signaling.

Biyu Hou1, Guifen Qiang1, Yuerong Zhao1,2, Xiuying Yang1, Xi Chen1, Yu Yan1, Xiaobo Wang1,2, Chenge Liu1, Li Zhang1, Guanhua Du1.   

Abstract

BACKGROUND/AIMS: Glomerular endothelium dysfunction leads to the progression of renal architectonic and functional abnormalities in early-stage diabetic nephropathy (DN). Advanced glycation end products (AGEs) and receptor for AGEs (RAGE) are proved to play important roles in diabetic nephropathy. This study investigated the role of Salvianolic acid A (SalA) on early-stage DN and its possible underlying mechanism.
METHODS: In vitro AGEs formation and breaking rate were measured to illustrate the effect of SalA on AGEs. Type 2 diabetic nephropathy rats were induced by high-fat diet and low-dose streptozocin (STZ). After eight-week treatment with SalA 1 mg/kg/day, 24h-urine protein, creatinine clearance was tested and renal structural injury was assessed by PAS and PASM staining. Primary glomerular endothelial cell permeability was evaluated after exposed to AGEs. AGEs-induced RhoA/ROCK and subsequently activated disarrange of cytoskeleton were assessed by western blot and immunofluorescence.
RESULTS: Biochemical assay and histological examination demonstrated that SalA markedly reduced endothelium loss and glomerular hyperfiltration, suppressed glomerular hypertrophy and mesangial matrix expansion, eventually reduced urinary albumin and ameliorated renal function. Further investigation suggested that SalA exerted its renoprotective effects through inhibiting AGE-RAGE signaling. It not only inhibited formation of AGEs and increased its breaking in vitro, but also reduced AGEs accumulation in vivo and downregulated RAGE expression. SalA restored glomerular endothelial permeability through suppressing AGEs-induced rearrangement of actin cytoskeleton via AGE-RAGE-RhoA/ ROCK pathway. Moreover, SalA attenuated oxidative stress induced by AGEs, subsequently alleviated inflammation and restored the disturbed autophagy in glomerular endothelial cell and diabetic rats via AGE-RAGE-Nox4 axis.
CONCLUSION: Our study indicated that SalA restored glomerular endothelial function and alleviated renal structural deterioration through inhibiting AGE-RAGE, thus effectively ameliorated early-stage diabetic nephropathy. SalA might be a promising therapeutic agent for the treatment of diabetic nephropathy.
© 2017 The Author(s). Published by S. Karger AG, Basel.

Entities:  

Keywords:  Advanced glycation end products; Diabetic nephropathy; Glomerular endothelia dysfunction; Salvianolic acid A

Mesh:

Substances:

Year:  2017        PMID: 29262395     DOI: 10.1159/000486154

Source DB:  PubMed          Journal:  Cell Physiol Biochem        ISSN: 1015-8987


  23 in total

1.  Effect of tocilizumab, an interleukin-6 inhibitor, on early stage streptozotocin-induced diabetic nephropathy in rats.

Authors:  Aly M Abdelrahman; Yousuf Al Suleimani; Asem Shalaby; Mohammed Ashique; Priyadarsini Manoj; Badreldin H Ali
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2019-04-25       Impact factor: 3.000

2.  Preparation of Ergosterol-Loaded Nanostructured Lipid Carriers for Enhancing Oral Bioavailability and Antidiabetic Nephropathy Effects.

Authors:  Zhonghua Dong; Sajid Iqbal; Zhongxi Zhao
Journal:  AAPS PharmSciTech       Date:  2020-01-13       Impact factor: 3.246

Review 3.  Diabetic Kidney Disease: From Pathogenesis to Novel Treatment Possibilities.

Authors:  Ara Aboolian; Sofia Urner; Michael Roden; Jay Chandra Jha; Karin Jandeleit-Dahm
Journal:  Handb Exp Pharmacol       Date:  2022

4.  Proximal tubular RAGE mediated the renal fibrosis in UUO model mice via upregulation of autophagy.

Authors:  Bohao Liu; Tianshi Sun; Huiling Li; Shuangfa Qiu; Yijian Li; Dongshan Zhang
Journal:  Cell Death Dis       Date:  2022-04-23       Impact factor: 9.685

5.  Some pharmacokinetic parameters of salvianolic acid A following single-dose oral administration to rats.

Authors:  Jialin Sun; Junke Song; Wen Zhang; Fanbo Jing; Wen Xu; Ping Leng; Xianghua Quan; Guanhua Du; Zhongguo Sui
Journal:  Pharm Biol       Date:  2018-12       Impact factor: 3.503

6.  Ergosterol Ameliorates Diabetic Nephropathy by Attenuating Mesangial Cell Proliferation and Extracellular Matrix Deposition via the TGF-β1/Smad2 Signaling Pathway.

Authors:  Zhonghua Dong; Yueyue Sun; Guangwei Wei; Siying Li; Zhongxi Zhao
Journal:  Nutrients       Date:  2019-02-25       Impact factor: 5.717

7.  Bushen Huoxue Attenuates Diabetes-Induced Cognitive Impairment by Improvement of Cerebral Microcirculation: Involvement of RhoA/ROCK/moesin and Src Signaling Pathways.

Authors:  Yuan Li; Quan Li; Chun-Shui Pan; Li Yan; Bai-He Hu; Yu-Ying Liu; Lei Yang; Ping Huang; Shao-Yang Zhao; Chuan-She Wang; Jing-Yu Fan; Xue-Mei Wang; Jing-Yan Han
Journal:  Front Physiol       Date:  2018-05-15       Impact factor: 4.566

8.  Aqueous Extract of Mori Folium Exerts Bone Protective Effect Through Regulation of Calcium and Redox Homeostasis via PTH/VDR/CaBP and AGEs/RAGE/Nox4/NF-κB Signaling in Diabetic Rats.

Authors:  Chenyue Liu; Ruyuan Zhu; Haixia Liu; Lin Li; Beibei Chen; Qiangqiang Jia; Lili Wang; Rufeng Ma; Simin Tian; Min Wang; Min Fu; Jianzhao Niu; Alexander N Orekhov; Sihua Gao; Dongwei Zhang; Baosheng Zhao
Journal:  Front Pharmacol       Date:  2018-11-06       Impact factor: 5.810

9.  Intermittent high glucose-induced oxidative stress modulates retinal pigmented epithelial cell autophagy and promotes cell survival via increased HMGB1.

Authors:  Wei Zhang; Jian Song; Yue Zhang; Yingxue Ma; Jing Yang; Guanghui He; Song Chen
Journal:  BMC Ophthalmol       Date:  2018-08-06       Impact factor: 2.209

10.  Comprehensive Lipidome Profiling of the Kidney in Early-Stage Diabetic Nephropathy.

Authors:  Biyu Hou; Ping He; Peng Ma; Xinyu Yang; Chunyang Xu; Sin Man Lam; Guanghou Shui; Xiuying Yang; Li Zhang; Guifen Qiang; Guanhua Du
Journal:  Front Endocrinol (Lausanne)       Date:  2020-06-19       Impact factor: 6.055

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.